Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002339
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
Sponsor:
Pfizer
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients
Status:
COMPLETED
Status Verified Date:
1996-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the safety toleration and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients including those with AIDS
Detailed Description:
Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8 weeks Patients are evaluated weekly and treatment continues for 2 weeks after resolution of symptoms Endoscopic exams and possibly biopsies are performed at baseline and at the end of treatment Patients undergo follow-up at 2 weeks post-treatment
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R-0220 | None | None | None |